ArticleJournal of neuro-oncology2018
Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors.
Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.The Cochrane database of systematic reviews · 2021Pooled it
- The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis.BMC cancer · 2020Pooled it
- CDKN2A deletion associated with poor prognosis in patients with TERT promoter wild-type, IDH wild-type glioblastoma.Brain tumor pathology · 2026Article
- Beyond Chronological Age: A Scoping Review of Neurosurgical Intervention for Central Nervous System Tumors in the Very Elderly.Current oncology (Toronto, Ont.) · 2026Article
- Mapping the global research landscape and innovations on elderly glioma: a bibliometric analysis.Frontiers in oncology · 2026Article
- Dynamic susceptibility contrast‑enhanced perfusion magnetic resonance imaging parameters for predictingOncology letters · 2024Article
- Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort.Acta neuropathologica communications · 2024Article
- Association of ADC of hyperintense lesions on FLAIR images with TERT promoter mutation status in glioblastoma IDH wild type.Surgical neurology international · 2024Article
- LRRFIP1, an epigenetically regulated gene, is a prognostic biomarker and predicts malignant phenotypes of glioma.CNS neuroscience & therapeutics · 2022Article
- Newly Diagnosed Glioblastoma in Elderly Patients.Current oncology reports · 2022Review
- Preoperative Apparent Diffusion Coefficient of Peritumoral Lesion Associate with Recurrence in Patients with Glioblastoma.Neurologia medico-chirurgica · 2022Article
- Comprehensive Analysis of Expression and Prognostic Value of MS4As in Glioma.Frontiers in genetics · 2022Article
- Prognostic Impact of the Combination ofJournal of neurosciences in rural practice · 2021Article
- Bioinformatics analysis of the prognostic value of NEK8 and its effects on immune cell infiltration in glioma.Journal of cellular and molecular medicine · 2021Article
- Review
- Clinical characteristics and risk factors of perioperative outcomes in elderly patients with intracranial tumors.Neurosurgical review · 2021Article
- Malignant Progression of an IDH Mutant Brainstem Glioma in Adult.NMC case report journal · 2021Article
- Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors.Pharmaceutics · 2020Review
- Relationships between recurrence patterns and subventricular zone involvement or CD133 expression in glioblastoma.Journal of neuro-oncology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study investigates the current state of clinical practice and molecular analysis for elderly patients with diffuse gliomas and aims to elucidate treatment outcomes and prognostic factors of patients with glioblastomas.
methodsWe collected elderly cases (≥ 70 years) diagnosed with primary diffuse gliomas and enrolled in Kansai Molecular Diagnosis Network for CNS Tumors. Clinical and pathological characteristics were analyzed retrospectively. Various factors were evaluated in univariate and multivariate models to examine their effects on overall survival.
resultsIncluded in the study were 140 elderly patients (WHO grade II: 7, III: 19, IV: 114), median age was 75 years. Sixty-seven patients (47.9%) had preoperative Karnofsky Performance Status score of ≥ 80. All patients underwent resection (gross-total: 20.0%, subtotal: 14.3%, partial: 39.3%, biopsy: 26.4%). Ninety-six of the patients (68.6%) received adjuvant treatment consisting of radiotherapy (RT) with temozolomide (TMZ). Seventy-eight of the patients (75.0%) received radiation dose of ≥ 50 Gy. MGMT promoter was methylated in 68 tumors (48.6%), IDH1/2 was wild-type in 129 tumors (92.1%), and TERT promoter was mutated in 78 of 128 tumors (60.9%). Median progression-free and overall survival of grade IV cases was 8.2 and 13.6 months, respectively. Higher age (≥ 80 years) and TERT promoter mutated were associated with shorter survival. Resection and adjuvant RT + TMZ were identified as independent factors for good prognosis.
conclusionsThis community-based study reveals characteristics and outcomes of elderly glioma patients in a real-world setting. Elderly patients have several potential factors for poor prognosis, but resection followed by RT + TMZ could lengthen duration of survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.